---
document_datetime: 2025-12-02 04:51:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo.html
document_name: kinpeygo.html
version: success
processing_time: 0.1180803
conversion_datetime: 2025-12-24 08:45:13.975525
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kinpeygo

[RSS](/en/individual-human-medicine.xml/67580)

##### Authorised

This medicine is authorised for use in the European Union

budesonide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kinpeygo](#news-on)
- [More information on Kinpeygo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kinpeygo is a medicine used to treat adults with primary immunoglobulin A nephropathy (IgAN). IgAN is a disease where the kidneys gradually stop working and eventually fail, requiring patients to undergo dialysis or have a kidney transplant. Kinpeygo is used in people who have at least 1 g of protein in their urine per day or a urine protein-to-creatinine ratio of at least 0.8 g/g (another measure of protein levels in the urine).

Kinpeygo is a 'hybrid medicine'. It is similar to a 'reference medicine' containing the same active substance, but is used for a different disease and is given in a different way. The reference medicine for Kinpeygo is Entocort.

IgAN is rare, and Kinpeygo was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 November 2016. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu-3-16-1778](http://www.ema.europa.eu/medicines/human/orphan-designations/eu-3-16-1778) .

Kinpeygo contains the active substance budesonide.

Expand section

Collapse section

## How is Kinpeygo used?

Kinpeygo can only be obtained with a prescription and is available as capsules to be taken by mouth.

Kinpeygo is taken once a day for 9 months. The doctor may decide to repeat the 9-month cycle if necessary.

For more information about using Kinpeygo, see the package leaflet or contact your doctor or pharmacist.

## How does Kinpeygo work?

IgAN is caused by the immune system (the body's natural defences) producing a faulty version of immunoglobulin A (IgA), a protein in the blood that identifies and attaches to specific foreign substances. In patients with this condition, faulty IgA builds up in the kidney, damaging them and preventing them from working properly.

The active substance in Kinpeygo, budesonide, is a corticosteroid. Corticosteroids have a wide range of effects that suppress the immune system. In particular, Kinpeygo is designed to release budesonide when it reaches the intestine, where it reduces the production of faulty IgA and thereby reduces IgA build-up and damage to the kidneys.

## What benefits of Kinpeygo have been shown in studies?

A main study involving 364 patients with IgAN showed that, after 9 months of treatment, patients taking Kinpeygo had a 34% reduction in proteinuria (excess protein in the urine, which can be a sign of kidney damage) compared with a 5% reduction in patients taking placebo (a dummy treatment). Long- term data showed that 15 months after the 9-month treatment period, patients who had received Kinpeygo had a 31% reduction in proteinuria compared with 1% for those who had received placebo. The study data also indicated that Kinpeygo slows the decline in kidney function, as seen in the change in estimated glomerular filtration rate (eGFR; a measure of how well the kidneys are working). A decrease in eGFR indicates a decline in kidney function. 15 months after the 9-month treatment period, eGFR had dropped by 7.5 ml/min/1.73m2 in people who had received Kinpeygo, compared with 13.5 ml/min/1.73m2 in those who had received placebo.

## What are the risks associated with Kinpeygo?

For the full list of side effects and restrictions with Kinpeygo, see the package leaflet.

The most common side effects with Kinpeygo include acne (which may affect around 1 in 10 people), and peripheral or facial oedema (build-up of fluids in the extremities or in the face), weight increase and increased levels of white blood cells, each of which may affect around 1 in 20 people. In clinical trials, these side effects were mild or moderate and resolved with time. For the full list of side effects of Kinpeygo, see the package leaflet.

Kinpeygo must not be used in patients with severe liver impairment (Child-Pugh Class C).

## Why is Kinpeygo authorised in the EU?

Kinpeygo has been shown to be effective at lowering the level of excess protein in the urine in patients with IgAN, and also appears to slow the decline in kidney function in adults with this disease.

Treatment with Kinpeygo was generally well tolerated, and side effects were in line with the known safety profile of budesonide.

The European Medicines Agency therefore decided that Kinpeygo's benefits are greater than its risks and it can be authorised for use in the EU.

Kinpeygo was originally given 'conditional authorisation'. The authorisation has now been switched to standard authorisation as the company has provided additional data requested by the Agency.

## What measures are being taken to ensure the safe and effective use of Kinpeygo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kinpeygo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kinpeygo are continuously monitored. Suspected side effects reported with Kinpeygo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kinpeygo

Kinpeygo received a conditional marketing authorisation valid throughout the EU on 19 May 2022. The conditional marketing authorisation was switched to a standard marketing authorisation on 24 July 2024.

Kinpeygo : EPAR - Medicine overview

English (EN) (122.19 KB - PDF)

**First published:** 18/07/2022

**Last updated:** 15/10/2024

[View](/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-460)

български (BG) (125.45 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/bg/documents/overview/kinpeygo-epar-medicine-overview_bg.pdf)

español (ES) (101.92 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/es/documents/overview/kinpeygo-epar-medicine-overview_es.pdf)

čeština (CS) (120.99 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/cs/documents/overview/kinpeygo-epar-medicine-overview_cs.pdf)

dansk (DA) (101.27 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/da/documents/overview/kinpeygo-epar-medicine-overview_da.pdf)

Deutsch (DE) (102.15 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/de/documents/overview/kinpeygo-epar-medicine-overview_de.pdf)

eesti keel (ET) (100.21 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/et/documents/overview/kinpeygo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.98 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/el/documents/overview/kinpeygo-epar-medicine-overview_el.pdf)

français (FR) (102.56 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/fr/documents/overview/kinpeygo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (115.96 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/hr/documents/overview/kinpeygo-epar-medicine-overview_hr.pdf)

italiano (IT) (101.68 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/it/documents/overview/kinpeygo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (130.47 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/lv/documents/overview/kinpeygo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (120.04 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/lt/documents/overview/kinpeygo-epar-medicine-overview_lt.pdf)

magyar (HU) (115.33 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/hu/documents/overview/kinpeygo-epar-medicine-overview_hu.pdf)

Malti (MT) (120.87 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/mt/documents/overview/kinpeygo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (101.98 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/nl/documents/overview/kinpeygo-epar-medicine-overview_nl.pdf)

polski (PL) (120.95 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/pl/documents/overview/kinpeygo-epar-medicine-overview_pl.pdf)

português (PT) (101.65 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/pt/documents/overview/kinpeygo-epar-medicine-overview_pt.pdf)

română (RO) (124.67 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/ro/documents/overview/kinpeygo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (120.04 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/sk/documents/overview/kinpeygo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (115.96 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/sl/documents/overview/kinpeygo-epar-medicine-overview_sl.pdf)

Suomi (FI) (101.16 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/fi/documents/overview/kinpeygo-epar-medicine-overview_fi.pdf)

svenska (SV) (101.06 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

15/10/2024

[View](/sv/documents/overview/kinpeygo-epar-medicine-overview_sv.pdf)

Kinpeygo : EPAR - Risk management plan

English (EN) (630.02 KB - PDF)

**First published:** 18/07/2022

**Last updated:** 06/11/2024

[View](/en/documents/rmp-summary/kinpeygo-epar-risk-management-plan_en.pdf)

## Product information

Kinpeygo : EPAR - Product Information

English (EN) (542.36 KB - PDF)

**First published:** 18/07/2022

**Last updated:** 11/02/2025

[View](/en/documents/product-information/kinpeygo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-2)

български (BG) (616.96 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/bg/documents/product-information/kinpeygo-epar-product-information_bg.pdf)

español (ES) (614.61 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/es/documents/product-information/kinpeygo-epar-product-information_es.pdf)

čeština (CS) (608.2 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/cs/documents/product-information/kinpeygo-epar-product-information_cs.pdf)

dansk (DA) (595.61 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/da/documents/product-information/kinpeygo-epar-product-information_da.pdf)

Deutsch (DE) (574.36 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/de/documents/product-information/kinpeygo-epar-product-information_de.pdf)

eesti keel (ET) (557.96 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/et/documents/product-information/kinpeygo-epar-product-information_et.pdf)

ελληνικά (EL) (649.68 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/el/documents/product-information/kinpeygo-epar-product-information_el.pdf)

français (FR) (637.84 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/fr/documents/product-information/kinpeygo-epar-product-information_fr.pdf)

hrvatski (HR) (596.67 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/hr/documents/product-information/kinpeygo-epar-product-information_hr.pdf)

íslenska (IS) (745.04 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/is/documents/product-information/kinpeygo-epar-product-information_is.pdf)

italiano (IT) (539.38 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/it/documents/product-information/kinpeygo-epar-product-information_it.pdf)

latviešu valoda (LV) (605.47 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/lv/documents/product-information/kinpeygo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (602 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/lt/documents/product-information/kinpeygo-epar-product-information_lt.pdf)

magyar (HU) (584.35 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/hu/documents/product-information/kinpeygo-epar-product-information_hu.pdf)

Malti (MT) (648.77 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/mt/documents/product-information/kinpeygo-epar-product-information_mt.pdf)

Nederlands (NL) (498.36 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/nl/documents/product-information/kinpeygo-epar-product-information_nl.pdf)

norsk (NO) (536.35 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/no/documents/product-information/kinpeygo-epar-product-information_no.pdf)

polski (PL) (571.89 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/pl/documents/product-information/kinpeygo-epar-product-information_pl.pdf)

português (PT) (812.82 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/pt/documents/product-information/kinpeygo-epar-product-information_pt.pdf)

română (RO) (854.74 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/ro/documents/product-information/kinpeygo-epar-product-information_ro.pdf)

slovenčina (SK) (871.32 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/sk/documents/product-information/kinpeygo-epar-product-information_sk.pdf)

slovenščina (SL) (753.31 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/sl/documents/product-information/kinpeygo-epar-product-information_sl.pdf)

Suomi (FI) (583.17 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/fi/documents/product-information/kinpeygo-epar-product-information_fi.pdf)

svenska (SV) (564.29 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/sv/documents/product-information/kinpeygo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000245976 11/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kinpeygo : EPAR - All authorised presentations

English (EN) (77.19 KB - PDF)

**First published:** 18/07/2022

**Last updated:** 11/02/2025

[View](/en/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-681)

български (BG) (85.13 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/bg/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_bg.pdf)

español (ES) (85.22 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/es/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.1 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/cs/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (67.43 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/da/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (68.33 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/de/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.97 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/et/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (101.8 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/el/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_el.pdf)

français (FR) (85.1 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/fr/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (104.67 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/hr/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (85.15 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/is/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (84.32 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/it/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (94.26 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/lv/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (105.32 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/lt/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (105.21 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/hu/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (104.05 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/mt/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (84.86 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/nl/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (85.15 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/no/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_no.pdf)

polski (PL) (105.36 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/pl/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_pl.pdf)

português (PT) (85.92 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/pt/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_pt.pdf)

română (RO) (93.32 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/ro/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.3 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/sk/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (79.39 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/sl/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (83.92 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/fi/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (61.54 KB - PDF)

**First published:**

18/07/2022

**Last updated:**

11/02/2025

[View](/sv/documents/all-authorised-presentations/kinpeygo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kinpeygo Active substance budesonide, micronised International non-proprietary name (INN) or common name budesonide Therapeutic area (MeSH) Glomerulonephritis, IGA Anatomical therapeutic chemical (ATC) code A07EA06

### Pharmacotherapeutic group

Antidiarrheals, intestinal antiinflammatory / antiinfective agents

### Therapeutic indication

Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).

## Authorisation details

EMA product number EMEA/H/C/005653

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Stada Arzneimittel AG

Stadastrasse 2-18

Opinion adopted 19/05/2022 Marketing authorisation issued 15/07/2022 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kinpeygo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (134.15 KB - PDF)

**First published:** 11/02/2025

[View](/en/documents/procedural-steps-after/kinpeygo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kinpeygo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (124.23 KB - PDF)

**First published:** 22/09/2022

**Last updated:** 11/02/2025

[View](/en/documents/procedural-steps-after/kinpeygo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kinpeygo-H-C-PSUSA-00011007-202312 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/452285/2024

English (EN) (93.38 KB - PDF)

**First published:** 27/09/2024

[View](/en/documents/scientific-conclusion/kinpeygo-h-c-psusa-00011007-202312-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Kinpeygo : Orphan maintenance assessment report - post-authorisation

Reference Number: EMA/OD/0000157484

English (EN) (282.12 KB - PDF)

**First published:** 07/08/2024

[View](/en/documents/orphan-maintenance-report-post/kinpeygo-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Kinpeygo-H-C-005653-II-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/291571/2024

English (EN) (3.86 MB - PDF)

**First published:** 30/07/2024

[View](/en/documents/variation-report/kinpeygo-h-c-005653-ii-008-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Kinpeygo (II-08)

Adopted

Reference Number: EMA/233577/2024

English (EN) (127.17 KB - PDF)

**First published:** 31/05/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinpeygo-ii-08_en.pdf)

## Initial marketing authorisation documents

Kinpeygo : EPAR - Public Assessment Report

Reference Number: EMA/570757/2022

English (EN) (5.42 MB - PDF)

**First published:** 23/08/2022

[View](/en/documents/assessment-report/kinpeygo-epar-public-assessment-report_en.pdf)

Kinpeygo : EPAR - Orphan Maintenance Assessment Report

Adopted

Reference Number: EMADOC-360526170-1063106

English (EN) (267.59 KB - PDF)

**First published:** 18/07/2022

[View](/en/documents/orphan-maintenance-report/kinpeygo-epar-orphan-maintenance-assessment-report_en.pdf)

CHMP summary of positive opinion for Kinpeygo

Adopted

Reference Number: EMA/253572/2022

English (EN) (161 KB - PDF)

**First published:** 20/05/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kinpeygo_en.pdf)

#### News on Kinpeygo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024) 31/05/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

#### More information on Kinpeygo

- [EU/3/16/1778 - orphan designation for treatment of primary IgA nephropathy](/en/medicines/human/orphan-designations/eu-3-16-1778)

**This page was last updated on** 11/02/2025

## Share this page

[Back to top](#main-content)